Summary for Tradename: IRESSA
Clinical Trials for: IRESSA
Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer
Status: Completed Condition: Head and Neck Cancer
Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Status: Completed Condition: Myelogenous Leukemia, Acute
Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)
Status: Completed Condition: Carcinoma, Non-Small-Cell Lung
Hydroxychloroquine and Gefitinib to Treat Lung Cancer
Status: Recruiting Condition: Non-small Cell Lung Cancer
ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
Status: Completed Condition: Skin Cancer
A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer
Status: Completed Condition: Breast Cancer
Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer
Status: Terminated Condition: BREAST CANCER
A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839
Status: Completed Condition: Nasopharyngeal Carcinoma
Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
Status: Completed Condition: Untreated Childhood Anaplastic Astrocytoma; Untreated Childhood Anaplastic Oligodendroglioma; Untreated Childhood Brain Stem Glioma; Untreated Childhood Giant Cell Glioblastoma; Untreated Childhood Glioblastoma; Untreated Childhood Gliomatosis Cerebri; Untreated Childhood Gliosarcoma; Untreated Childhood Oligodendroglioma
High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
Status: Completed Condition: Non-Small Cell Lung Cancer
Courtesy of ClinicalTrials.org
See more clinical trials for this drug
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Type||RLD||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|TABLET;ORAL||021399||May 5, 2003||DISCN||No||5,770,599||<disabled>||Y||Y||<disabled>|
|This preview shows a limited data set|
Complete access is available with a Subscription
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639